FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
25.14k
0
0
0
0
12.57k
12.57k
0
25.14k
-12.57k
-12.57k
1.64M
652.07k
1.67M
1.73M
903.36k
364.18k
1.21M
1.46M
739.82k
287.88k
453.3k
265.04k
0
0
0
-12.57k
739.82k
287.88k
453.3k
277.61k
0
0
0
0
-1.64M
-652.07k
-1.67M
-1.74M
89.44k
11.28k
60.83k
14.06k
-1.55M
-640.78k
-1.61M
-1.72M
0
0
0
-2
-1.55M
-640.78k
-1.61M
-1.72M
-0.33
-0.14
-0.36
-0.39
-0.33
-0.14
-0.36
-0.39
4.71M
4.53M
4.44M
4.44M
4.71M
4.53M
4.44M
4.44M
-1.54M
-639.49k
-1.59M
-1.71M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-34.75M
-34.11M
-32.5M
-30.78M
-1.55M
-640.78k
-1.61M
-1.72M
0
0
0
0
0
0
0
0
-36.3M
-34.75M
-34.11M
-32.5M
-1.55M
-640.78k
-1.61M
-1.72M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
73.05k
85.62k
98.19k
110.76k
12.57k
12.57k
12.57k
12.57k
0
0
0
0
60.48k
73.05k
85.62k
98.19k
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.